NCT07371585
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07371585
Title Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management (TOP-REAL)
Acronym TOP-REAL
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors SOLTI Breast Cancer Research Group
Indications
Therapies
Age Groups: adult | senior
Covered Countries FRA | ESP | DEU

Facility Status City State Zip Country Details
Gustave Roussy Villejuif 94805 France Details
Klinikum der Universitaet Muenchen AöR München Germany Details
Hospital Universitari Vall d'Hebrón Barcelona Barcelona 08035 Spain Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field